Altered splicing machinery in lung carcinoids unveils NOVA1, PRPF8 and SRSF10 as novel candidates to understand tumor biology and expand biomarker discovery
Ricardo Blázquez‐Encinas(Instituto Maimónides de Investigación Biomédica de Córdoba), Justo P. Castaño(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition)
Cited by 12
Related Papers
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
|Pharmacological Reviews|2018|251
Molecular Pathogenesis of Neuroendocrine Tumors: Implications for Current and Future Therapeutic Approaches
|Clinical Cancer Research|2013|89
Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug
|Journal of Experimental & Clinical Cancer Research|2021|58